Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Director comp.
Quarterly results
Inv. presentation
Asset disposition

RAPT Therapeutics, Inc. (RAPT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 4 HO WILLIAM (Chief Medical Officer) has filed a Form 4 on RAPT Therapeutics, Inc.
Txns: Sold 2,500 shares @ $15.77, valued at $39.4k
10/03/2023 144 Form 144 - Report of proposed sale of securities:
08/22/2023 4 HO WILLIAM (Chief Medical Officer) has filed a Form 4 on RAPT Therapeutics, Inc.
Txns: Sold 2,500 shares @ $18.92, valued at $47.3k
08/18/2023 144 Form 144 - Report of proposed sale of securities:
08/18/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/17/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/11/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
08/11/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 8-K Quarterly results
08/03/2023 4 HO WILLIAM (Chief Medical Officer) has filed a Form 4 on RAPT Therapeutics, Inc.
Txns: Exercised 460 options to buy @ $12, valued at $5.5k
06/12/2023 SC 13G/A PRICE T ROWE ASSOCIATES INC reports a 10.4% stake in RAPT THERAPEUTICS INC
05/26/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/25/2023 4 Robbins Wendye (Director) has filed a Form 4 on RAPT Therapeutics, Inc.
Txns: Granted 12,940 options to buy @ $20.93, valued at $270.8k
05/25/2023 4 RIEFLIN WILLIAM JL (Director) has filed a Form 4 on RAPT Therapeutics, Inc.
Txns: Granted 12,940 options to buy @ $20.93, valued at $270.8k
05/25/2023 4 Lyons-Williams Lori (Director) has filed a Form 4 on RAPT Therapeutics, Inc.
Txns: Granted 12,940 options to buy @ $20.93, valued at $270.8k
05/25/2023 4 Kozick Linda (Director) has filed a Form 4 on RAPT Therapeutics, Inc.
Txns: Granted 12,940 options to buy @ $20.93, valued at $270.8k
05/25/2023 4 GRAY MARY ANN (Director) has filed a Form 4 on RAPT Therapeutics, Inc.
Txns: Granted 12,940 options to buy @ $20.93, valued at $270.8k
05/25/2023 4 Giordano Michael F (Director) has filed a Form 4 on RAPT Therapeutics, Inc.
Txns: Granted 12,940 options to buy @ $20.93, valued at $270.8k
05/11/2023 8-K Quarterly results
Docs: "RAPT Therapeutics Reports First Quarter 2023 Financial Results Company maintains strong cash position of $231.6 million SOUTH SAN FRANCISCO, Calif. – – RAPT Therapeutics, Inc. , a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the first quarter ended March 31, 2023. “In 2023, we are continuing to focus on advancing our two lead programs, RPT193 and FLX475,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “In the first quarter, we expanded our RPT193 program with the initiation of a Phase 2a clinical trial in asthma. We co..."
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/19/2023 144 Form 144 - Report of proposed sale of securities:
04/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/15/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/14/2023 8-K Investor presentation, Quarterly results
Docs: "RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results Company maintains strong cash position of $249.1 million SOUTH SAN FRANCISCO, Calif. – – RAPT Therapeutics, Inc. , a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the fourth quarter and year ended December 31, 2022. “2022 was an important year of progress, as we advanced both of our two lead programs, RPT193 and FLX475, in inflammatory disease and cancer, respectively,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “This progress has positioned us ...",
"29 8 15 43"
03/14/2023 10-K Annual Report for the period ended December 31, 2022
03/13/2023 4 HO WILLIAM (Chief Medical Officer) has filed a Form 4 on RAPT Therapeutics, Inc.
Txns: Sold 5,000 shares @ $29.62, valued at $148.1k
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/06/2023 4 HO WILLIAM (Chief Medical Officer) has filed a Form 4 on RAPT Therapeutics, Inc.
Txns: Exercised 460 options to buy @ $12, valued at $5.5k
02/14/2023 SC 13G/A PERCEPTIVE ADVISORS LLC reports a 5.3% stake in RAPT Therapeutics, Inc.
02/14/2023 SC 13G/A PRICE T ROWE ASSOCIATES INC reports a 9.9% stake in RAPT THERAPEUTICS INC
02/10/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/10/2023 SC 13G/A FMR LLC reports a 11.6% stake in RAPT THERAPEUTICS INC
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy